How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?

- Tiong, Ing Soo, Wall, Meaghan, Marlton, Paula, Johnston, Amanda, Enjeti, Anoop, Fong, Chun Yew, Cull, Gavin, Larsen, Stephen, Kennedy, Glen, Schwarer, Anthony, Kipp, David, Ramanathan, Sundra, Bajel, Ashish, Verner, Emma, Tiley, Campbell, Morris, E, Hahn, U, Moore, J, Taper, J, Purtill, D, Warburton, P, Stevenson, W, Murphy, N, Kalro, Akash, Tan, P, Beligaswatte, A, Mutsando, H, Hertzberg, M, Shortt, J, Szabo, F, Dunne, K, Wei, AH, Australasian Leukaemia and Lymphoma Group (ALLG),, Fleming, Shaun, Roberts, Andrew W., Thiagarajah, Nisha, Chua, Chong Chyn, Latimer, Maya, Yeung, David

Reporting bone marrow biopsies for myelodysplastic neoplasms and acute myeloid leukaemia incorporating WHO 5th edition and ICC 2022 classification systems: ALLG/RCPA joint committee consensus recommendations

- Ng, Ashley P., Adams, Rebecca, Tiong, Ing Soo, Seymour, Louise, Talaulikar, Dipti, Palfreyman, Emma, Enjeti, Anoop, Tate, Courtney

Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement

- Enjeti, Anoop K., Agarwal, Rishu, Singhal, Deepak, Tate, Courtney, Tiong, Ing Soo, Ross, David M., Blombery, Piers, Chee, Lynette, Chua, Chong Chyn, Grigg, Andrew, Hamad, Nada, Iland, Harry, Lane, Steven, Perkins, Andrew

Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: Results from a phase Ib/II study

- Wei, Andrew H., Strickland, Stephen A., Chyla, Brenda, Popovic, Relja, Salem, Ahmed Hamed, Agarwal, Suresh, Xu, Tu, Fakouhi, Kaffa M., Humerickhouse, Rod, Hong, Wan-Jen, Hayslip, John, Roboz, Gail J., Hou, Jing-Zhou, Fiedler, Walter, Lin, Tara L., Walter, Roland B., Enjeti, Anoop, Tiong, Ing Soo, Savona, Michael, Lee, Sangmin